Raymond James Financial
VTGN icon

Raymond James Financial’s VistaGen Therapeutics VTGN Stock Holding History

Raymond James Financial’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.51K Buy
+14,884
New +$9.04K ﹤0.01% 5260
2025
Q3 		– Sell
-6,410
Closed -$12.8K – 6755
2025
Q2 		$12.8K Buy
+6,410
New +$14.6K ﹤0.01% 5805

Other funds holding VTGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Raymond James Financial's VTGN Position: Q1 2026 in Review

Raymond James Financial opened a new position in VistaGen Therapeutics (VTGN) in Q1 2026: 14,884 shares worth $8.51K. The stake represents ﹤0.01% of the portfolio and ranks #5260 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in VTGN as recently as Q2 2025.

Raymond James Financial first reported a position in VTGN in Q2 2025 and has held it in 2 quarters since. The position peaked at $12.8K in Q2 2025. 56 funds tracked by Wall St. Rank hold VTGN as of Q1 2026.

  • Raymond James Financial held 14,884 shares of VistaGen Therapeutics worth $8.51K as of Q1 2026.
  • VistaGen Therapeutics was a new Raymond James Financial position in Q1 2026.
  • VistaGen Therapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q1 2026, its #5260 holding.
  • Raymond James Financial first reported a position in VistaGen Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Raymond James Financial's VistaGen Therapeutics position peaked at $12.8K in Q2 2025.
  • 56 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q1 2026.

Based on Raymond James Financial's 13F filing for Q1 2026, filed 14 May 2026.